Prima BioMed (NASDAQ:IMMP) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Prima BioMed (NASDAQ:IMMP) from a hold rating to a sell rating in a report issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prima BioMed in a report on Monday, December 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Prima BioMed Stock Up 0.4%

NASDAQ:IMMP opened at $2.63 on Friday. The company has a 50 day moving average price of $2.01 and a 200-day moving average price of $1.82. Prima BioMed has a 1-year low of $1.32 and a 1-year high of $3.53.

Hedge Funds Weigh In On Prima BioMed

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC grew its stake in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. 2.32% of the stock is owned by hedge funds and other institutional investors.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.